BACKGROUND: Mannose-binding lectin (MBL) is a serum lectin involved in innate immune response. Low serum MBL concentration may constitute a risk factor for infection in patients receiving myelosuppressive chemotherapy. METHODS: We conducted a prospective, observational study that assessed MBL concentration as a risk factor for infection in patients with hematological malignancy who were hospitalized to undergo at least 1 chemotherapy cycle. MBL deficiency was defined using an algorithm that considered the serum MBL concentration and the MBL genotype. The primary end point was the ratio of duration of febrile neutropenia to the duration of neutropenia. Secondary end points included the incidence of severe infection (e.g., sepsis, pneumonia, bacteremia, and invasive fungal infection). Logistic regression analysis was conducted, and Fisher's exact test was used to analyze binary outcomes, and Kaplan-Meier estimates and log rank tests were used for time-to-event variables. RESULTS: We analyzed 255 patients who received 569 cycles of chemotherapy. The median duration of neutropenia per cycle was 7 days (interquartile range, 0-13 days). Sixty-two patients (24%) were found to have MBL deficiency. Febrile neutropenia occurred at least once in 200 patients. No difference in the primary outcome was seen. The incidence of severe infection was higher among MBL-deficient patients than among non-MBL-deficient patients (1.96 vs. 1.34 cases per 100 days for analysis of all patients [P=.008] and 1.85 vs. 0.94 cases per 100 days excluding patients with acute leukemia [P<.001]). CONCLUSIONS: MBL deficiency does not predispose adults with hematological cancer to more-frequent or more-prolonged febrile episodes during myelosuppressive chemotherapy, but MBL-deficient patients have a greater number of severe infections and experience their first severe infection earlier, compared with nondeficient patients.
BACKGROUND:Mannose-binding lectin (MBL) is a serum lectin involved in innate immune response. Low serum MBL concentration may constitute a risk factor for infection in patients receiving myelosuppressive chemotherapy. METHODS: We conducted a prospective, observational study that assessed MBL concentration as a risk factor for infection in patients with hematological malignancy who were hospitalized to undergo at least 1 chemotherapy cycle. MBL deficiency was defined using an algorithm that considered the serum MBL concentration and the MBL genotype. The primary end point was the ratio of duration of febrile neutropenia to the duration of neutropenia. Secondary end points included the incidence of severe infection (e.g., sepsis, pneumonia, bacteremia, and invasive fungal infection). Logistic regression analysis was conducted, and Fisher's exact test was used to analyze binary outcomes, and Kaplan-Meier estimates and log rank tests were used for time-to-event variables. RESULTS: We analyzed 255 patients who received 569 cycles of chemotherapy. The median duration of neutropenia per cycle was 7 days (interquartile range, 0-13 days). Sixty-two patients (24%) were found to have MBL deficiency. Febrile neutropenia occurred at least once in 200 patients. No difference in the primary outcome was seen. The incidence of severe infection was higher among MBL-deficientpatients than among non-MBL-deficientpatients (1.96 vs. 1.34 cases per 100 days for analysis of all patients [P=.008] and 1.85 vs. 0.94 cases per 100 days excluding patients with acute leukemia [P<.001]). CONCLUSIONS:MBL deficiency does not predispose adults with hematological cancer to more-frequent or more-prolonged febrile episodes during myelosuppressive chemotherapy, but MBL-deficientpatients have a greater number of severe infections and experience their first severe infection earlier, compared with nondeficient patients.
Authors: Ferenc Fekete; Balázs Fadgyas; Éva Papp; Ágnes Szilágyi; Zoltán Prohászka; Brigitta Müller; Gábor Kovács Journal: Pathol Oncol Res Date: 2015-10-03 Impact factor: 3.201
Authors: Jessica M van der Bol; Floris A de Jong; Ron H van Schaik; Alex Sparreboom; Marianne A van Fessem; Fleur E van de Geijn; Paul L van Daele; Jaap Verweij; Stefan Sleijfer; Ron H Mathijssen Journal: Oncologist Date: 2010-10-07
Authors: Stefan Geiss-Liebisch; Suzan H M Rooijakkers; Agnieszka Beczala; Patricia Sanchez-Carballo; Karolina Kruszynska; Christian Repp; Tuerkan Sakinc; Evgeny Vinogradov; Otto Holst; Johannes Huebner; Christian Theilacker Journal: J Biol Chem Date: 2012-08-20 Impact factor: 5.157
Authors: O W Neth; U Bacher; P Das; T Zabelina; H Kabisch; N Kroeger; F Ayuk; M Lioznov; O Waschke; B Fehse; R Thiébaut; R M Haston; N Klein; A R Zander Journal: Bone Marrow Transplant Date: 2009-05-11 Impact factor: 5.483
Authors: Michelle Wong; Lars Öhrmalm; Kristina Broliden; Carl Aust; Martin Hibberd; Thomas Tolfvenstam Journal: PLoS One Date: 2012-02-17 Impact factor: 3.240
Authors: Ana Moreto; Concepción Fariñas-Alvarez; Maria Puente; Javier Gonzalo Ocejo-Vinyals; Pablo Sánchez-Velasco; Juan Pablo Horcajada; Ana Batlle; Carmen Montes; Francisca Santos; Eulogio Conde; Maria-Carmen Fariñas Journal: BMC Immunol Date: 2014-05-03 Impact factor: 3.615